Global Radiopharmaceuticals Market Projected to Reach USD 25.88 Billion by 2035
News related to:Vectomat Insights · 2 min read
The global radiopharmaceuticals market is expected to expand significantly, reaching a projected value of USD 25.88 billion by 2035, according to Vectomat Insights. This growth is driven by a compound annual growth rate (CAGR) of 10.84%, with therapeutic radiopharmaceuticals outpacing diagnostics in the coming years.
While diagnostics currently hold a larger share of the market, accounting for 57.0% (USD 5,272.5 million) in 2025, therapeutic radiopharmaceuticals are growing at a faster rate of 15.44% CAGR. By 2035, therapeutic radiopharmaceuticals are projected to reach USD 16,716.9 million, overtaking diagnostics by 2029.
Isotopes and applications within the radiopharmaceuticals market are also showing significant shifts. Technetium-99m, the largest isotope share at 33.7%, is currently leading the way. However, Fluorine-18 is growing at a faster rate of 15.59% CAGR, indicating a potential shift in the isotopes used in radiopharmaceuticals.
Applications in oncology dominate the market at 46.8%, while neurology is leading the growth in applications at 15.17% annually. These trends suggest a growing focus on treatments and diagnostics in these areas.
Market momentum is being fueled by several key factors. Notable among these are expanded FDA approvals, such as Novartis' Pluvicto for hormone-sensitive prostate cancer, and updated Medicare reimbursement policies. These developments are expected to drive continued growth in the radiopharmaceuticals market.
Geographically, North America leads the global market with a 40.3% share, valued at USD 3,727.2 million in 2025, with the U.S. accounting for USD 2,929.2 million. Europe follows with a 25.9% share, while Asia-Pacific is expected to see the fastest regional expansion.
Industry consolidation is also a significant trend. Major mergers and acquisitions include Curium's merger agreement with Lantheus Holdings, valued at up to USD 8 billion, Telix Pharmaceuticals' acquisition of ITM Isotope Technologies Munich for USD 1.65 billion upfront, and BWXT's divestiture of its medical isotope division to Nordic Capital.
Despite these positive trends, the market faces several challenges. Aging Mo-99 research reactors, price compression, and strict manufacturing regulations are expected to pose hurdles to continued growth.
Vectomat Insights, an independent market research and intelligence firm, provides comprehensive analysis and forecasts for the radiopharmaceuticals market. Their 10-year forecasts, country-level breakdowns across 35+ countries, and competitive intelligence are trusted by corporate strategy teams, R&D leaders, and institutional investors.